TGen, Deepcell Partner to Study Melanoma Single-Cell Morphology, Genomics
Source: GenomeWeb, February 2022
NEW YORK – The Translational Genomics Research Institute (TGen) and Menlo Park-based Deepcell said Tuesday that they have partnered to conduct research using Deepcell’s artificial intelligence-powered imaging platform to analyze individual live cells in real time.
Financial terms of the agreement were not disclosed, but the partnership involves TGen’s scientific technology assessment research team (START) joining the Deepcell technology access program. START is a new arm of the institute, tasked with scouting and onboarding new technologies that can then be handed off to TGen and the greater City of Hope enterprise.
According to the companies, their first joint effort will be a pilot study in melanoma, a disease for which TGen has collected decades of genomic research and cell-based models.